Asset Details
Do you wish to reserve the book?
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
Do you wish to request the book?
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
2011
Overview
► Influenza B strains from 2 lineages co-circulate, but vaccines contain 1 B strain. ► Q/LAIV (live attenuated influenza vaccine with 2 B strains) was studied in adults. ► The immunogenicity of Q/LAIV was noninferior to that of trivalent LAIV. ► The safety profile of Q/LAIV was similar to that of T/LAIV.
Trivalent seasonal influenza vaccines contain 2 A strains and 1 B strain. B strains of 2 antigenically distinct lineages, Yamagata and Victoria, have been co-circulating annually, and the B strain included in vaccines often has not been a lineage match to the major circulating strain. Thus, a vaccine containing B strains from both lineages could broaden protection against influenza. Quadrivalent live attenuated influenza vaccine (Q/LAIV) is an investigational 4-strain formulation of LAIV that contains 2 A strains, A/H1N1 and A/H3N2, and 2 B strains, 1 from each lineage.
A randomized, double-blind, active-controlled study of Q/LAIV was conducted in 1800 adults aged 18–49 years to compare the immunogenicity and safety of Q/LAIV to trivalent LAIV (T/LAIV). Subjects were randomized 4:1:1 to receive an intranasal dose of Q/LAIV (n=1200) or 1 of 2 matching T/LAIV vaccines, each containing 1 of the B strains included in Q/LAIV (n=600 total). The primary endpoint was the comparison of the post-vaccination strain-specific geometric mean titers (GMT) of hemagglutination inhibition antibody in Q/LAIV recipients to those in T/LAIV recipients, with immunologic noninferiority of Q/LAIV to be demonstrated if the upper bound of the 2-sided 95% confidence interval (CI) for the ratio of the GMTs [T/LAIV divided by Q/LAIV] was ≤1.5 for all strains.
Q/LAIV met the criteria for noninferiority: the ratios of the GMTs for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 1.09 (95% CI, 1.01–1.18), 1.05 (95% CI, 0.96–1.14), 1.10 (95% CI, 0.97–1.25), and 0.92 (95% CI, 0.82–1.03), respectively. Solicited symptoms and adverse events were similar in the Q/LAIV and T/LAIV arms. Q/LAIV may confer increased protection against influenza by targeting B strains from both lineages.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
/ Adult
/ adults
/ Age
/ Biological and medical sciences
/ Consent
/ Fundamental and applied biological sciences. Psychology
/ Hemagglutination Inhibition Tests
/ Humans
/ Influenza A Virus, H1N1 Subtype - immunology
/ Influenza A Virus, H3N2 Subtype - immunology
/ Influenza B virus - immunology
/ Influenza Vaccines - adverse effects
/ Influenza Vaccines - immunology
/ Influenza, Human - immunology
/ Influenza, Human - prevention & control
/ Vaccines
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, Attenuated - adverse effects
/ Vaccines, Attenuated - immunology
/ Viruses
